These descriptive data suggest that CD11b-mediated leukocyte infiltration is biologically relevant, leading to the hypothesis that targeted therapeutic modulation of CD11b-mediated leukocyte trafficking could effectively treat chronic neuropathic pain associated with associated peripheral neuropathies in patients. This evidence concerns the gene ITGAM and peripheral neuropathy.